444 related articles for article (PubMed ID: 35717820)
1. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
2. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
[TBL] [Abstract][Full Text] [Related]
3. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
Kroeger N; Xie W; Lee JL; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Kollmannsberger CK; Tan MH; North SA; Rini BI; Choueiri TK; Heng DY
Cancer; 2013 Aug; 119(16):2999-3006. PubMed ID: 23696129
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database.
Koguchi T; Naito S; Hatakeyama S; Numakura K; Muto Y; Kato R; Kojima T; Kawasaki Y; Morozumi K; Kandori S; Kawamura S; Nishiyama H; Ito A; Habuchi T; Obara W; Ohyama C; Tsuchiya N; Kojima Y
Cancer Med; 2023 Nov; 12(22):20677-20689. PubMed ID: 37905674
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
7. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
8. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
9. Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.
Carril-Ajuria L; Colomba E; Cerbone L; Romero-Ferreiro C; Crouzet L; Laguerre B; Thibault C; Vicier C; de Velasco G; Fléchon A; Saldana C; Benusiglio PR; Bressac-de Paillerets B; Guillaud-Bataille M; Gaignard P; Scoazec JY; Richard S; Caron O; Escudier B; Albiges L
Eur J Cancer; 2021 Jul; 151():106-114. PubMed ID: 33975058
[TBL] [Abstract][Full Text] [Related]
10. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis.
Araujo DV; Wells JC; Hansen AR; Dizman N; Pal SK; Beuselinck B; Donskov F; Gan CL; Yan F; Tran B; Kollmannsberger CK; de Velasco G; Yuasa T; Reaume MN; Ernst DS; Powles T; Bjarnason GA; Choueiri TK; Heng DYC; Dudani S
J Geriatr Oncol; 2021 Jun; 12(5):820-826. PubMed ID: 33674246
[TBL] [Abstract][Full Text] [Related]
12. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk.
Kartolo A; Holstead RG; Duran I; Robinson AG; Vera-Badillo FE
Urology; 2021 Nov; 157():8-14. PubMed ID: 34461142
[TBL] [Abstract][Full Text] [Related]
14. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
Schutz FA; Xie W; Donskov F; Sircar M; McDermott DF; Rini BI; Agarwal N; Pal SK; Srinivas S; Kollmannsberger C; North SA; Wood LA; Vaishampayan U; Tan MH; Mackenzie MJ; Lee JL; Rha SY; Yuasa T; Heng DY; Choueiri TK
Eur Urol; 2014 Apr; 65(4):723-30. PubMed ID: 24184025
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
16. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
18. Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
Guram K; Huang J; Mouchati C; Abdallah N; Jani C; Navani V; Xie W; El Zarif T; Adib E; Gebrael G; Agarwal N; Li H; Labaki C; Labban M; Ruiz Morales JM; Choueiri TK; Chin Heng DY; Mittal A; Hansen AR; Rose BS; McKay RR
Cancer; 2024 Jun; 130(11):2003-2013. PubMed ID: 38297953
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs.
Lee CH; Hötker AM; Voss MH; Feldman DR; Woo KM; Patil S; Coskey DT; Akin O; Hsieh JJ; Motzer RJ
Clin Genitourin Cancer; 2016 Feb; 14(1):56-62. PubMed ID: 26404107
[TBL] [Abstract][Full Text] [Related]
20. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]